Literature DB >> 12949733

Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer.

Arne Scholz1, Sandra Heinze, Katharina M Detjen, Michael Peters, Martina Welzel, Peter Hauff, Michael Schirner, Bertram Wiedenmann, Stefan Rosewicz.   

Abstract

BACKGROUND & AIMS: Constitutive activation of signal transducer and activator of transcription 3 (STAT3) has been implicated in regulation of growth and malignant transformation. We therefore analyzed the expression and biologic significance of STAT3 in human pancreatic cancer cells.
METHODS: Expression and activation of STAT3 were investigated by immunohistochemistry and immunoblotting. Functional inactivation of STAT3 was achieved by stable transfection of dominant-negative STAT3 constructs in 2 pancreatic cancer cell lines and confirmed by electrophoretic mobility shift assay and immunoblotting. Cell proliferation and tumorigenicity were evaluated by cell counting, colony formation in soft agar, and xenotransplantation in nude mice. STAT3-dependent cell cycle distribution was monitored by flow cytometry, immunoprecipitation, immunoblotting, and histone H1 and GST-Rb kinase assays.
RESULTS: Compared with nontransformed human pancreas, activated STAT3 is overexpressed in ductal carcinoma cells but not in ducts from chronic pancreatitis. Constitutive activation was also observed in all human pancreatic cancer cell lines examined. Functional inactivation of STAT3 resulted in significant inhibition of anchorage-dependent and -independent proliferation in vitro and reduced tumor growth in vivo. Cell cycle analysis showed a delay of G(1)/S-phase progression due to inhibition of cyclin-dependent kinase 2 activity based on increased expression of p21(WAF1) in vitro and in vivo. Blocking of the STAT3 upstream activator Janus kinase 2 by tyrphostin also resulted in growth arrest because of delayed G(1)/S-phase progression and increased expression of p21(WAF1).
CONCLUSIONS: On malignant transformation, activated STAT3 promotes cellular proliferation by acceleration of G(1)/S-phase progression and thereby contributes to the malignant phenotype of human pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949733     DOI: 10.1016/s0016-5085(03)01064-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  108 in total

Review 1.  Chemoprevention strategies for pancreatic cancer.

Authors:  Silvia D Stan; Shivendra V Singh; Randall E Brand
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

2.  STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer.

Authors:  Jing-Yu Deng; Dan Sun; Xiang-Yu Liu; Yi Pan; Han Liang
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

3.  Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.

Authors:  Xiang-Lin Tan; Kalyan K Bhattacharyya; Shamit K Dutta; William R Bamlet; Kari G Rabe; Enfeng Wang; Thomas C Smyrk; Ann L Oberg; Gloria M Petersen; Debabrata Mukhopadhyay
Journal:  Pancreas       Date:  2015-05       Impact factor: 3.327

4.  Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic acid against pancreatic cancer cells.

Authors:  Myrna Hurtado; Laszlo Prokai; Umesh T Sankpal; Blair Levesque; Rajasekhar Maram; Jaya Chhabra; Deondra T Brown; Raj K Gurung; Alvin A Holder; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Process Biochem       Date:  2019-10-30       Impact factor: 3.757

5.  Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation.

Authors:  Takeshi Miyatsuka; Hideaki Kaneto; Toshihiko Shiraiwa; Taka-aki Matsuoka; Kaoru Yamamoto; Ken Kato; Yumiko Nakamura; Shizuo Akira; Kiyoshi Takeda; Yoshitaka Kajimoto; Yoshimitsu Yamasaki; Eric P Sandgren; Yoshiya Kawaguchi; Christopher V E Wright; Yoshio Fujitani
Journal:  Genes Dev       Date:  2006-06-01       Impact factor: 11.361

Review 6.  [Pathogenesis of the ductal pancreatic adenocarcinoma: implications for future therapies?].

Authors:  G Schneider; R M Schmid
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

7.  JAK V617F missense mutation is absent in pancreatic cancer.

Authors:  H M Kocher; L Mears; N C Lea; K Raj; G J Mufti
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 8.  Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

Authors:  Ying Zeng; Agnieszka A Rucki; Xu Che; Lei Zheng
Journal:  J Gastrointest Oncol       Date:  2017-06

9.  Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.

Authors:  Jingjing Gong; Jianping Xie; Roble Bedolla; Paul Rivas; Divya Chakravarthy; James W Freeman; Robert Reddick; Scott Kopetz; Amanda Peterson; Huamin Wang; Susan M Fischer; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

Review 10.  Anti-cancer therapies that utilize cell penetrating peptides.

Authors:  Benjamin G Bitler; Joyce A Schroeder
Journal:  Recent Pat Anticancer Drug Discov       Date:  2010-06       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.